What is Otogenetics?
Otogenetics operates as a CAP-accredited clinical laboratory specializing in Next Generation Sequencing (NGS)-based genetic testing and molecular diagnostics. Their comprehensive service portfolio includes Carrier Screening, Non-Invasive Prenatal Testing, Hereditary Cancer Risk Assessment, and testing for congenital hearing loss. By serving both patients and physicians, Otogenetics is dedicated to advancing precision medicine and fostering the education of future medical professionals in genetic diagnostics.
How much funding has Otogenetics raised?
Otogenetics has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in Otogenetics
PPP
Public-Private Partnership
What's next for Otogenetics?
The substantial late-stage funding suggests Otogenetics is poised for significant expansion, likely focusing on scaling its diagnostic services, enhancing its technological infrastructure, and potentially broadening its market reach. This strategic investment will likely fuel further research and development in NGS applications, solidifying its role in the precision medicine landscape and reinforcing its commitment to training the next generation of geneticists.
See full Otogenetics company page
